Files
aevolution/docs/engineering/M11_4_DELIVERY_PLAN.md
T
dingo f6e545c7ab
Foundation / checks (checks) (push) Successful in 5s
Foundation / checks (client) (push) Successful in 5s
Foundation / checks (deploy) (push) Successful in 5s
Foundation / checks (ecs) (push) Successful in 4s
Foundation / checks (network) (push) Successful in 5s
Foundation / checks (postgres) (push) Successful in 4s
Foundation / checks (tsan) (push) Successful in 4s
Foundation / postgres-tools (push) Successful in 5s
Foundation / image (push) Successful in 5s
Foundation / server-image (push) Successful in 5s
Record validated M11.4a and 11.4b gates
2026-10-11 08:13:33 -04:00

77 lines
5.4 KiB
Markdown

# M11.4: Apply earned mutation choices through development
M11.4 connects the accepted M3 seeded candidate generator and immutable lineage
archive to a living player organism. The game rule authority is ADR-0098; the
first funded transition is ADR-0118. Candidate counts, event cadence, eligibility
thresholds and resource targets remain trial values until informed by the 11.3
probe and later repeated-life tests. No class tree, candidate ranking or automatic
wildlife mutation is introduced.
## Boundaries
Read PROJECT_VISION, ENGINEERING_CONSTITUTION, GENOME_MODEL,
ADR-0030 through ADR-0034, ADR-0098, ADR-0108 through
ADR-0110 and the cellular checkpoint schema before changing the owner. Preserve
the M3 pure generator's seed/context rules and genome v1/v2 compatibility. The
headless biology library must not acquire transport, UI, database or Kubernetes
dependencies. Every accepted choice must be one durable action whose outcome,
successor genome, body transfer and life revision recover together.
The 11.3 hands-on probe is now executable in the engineering client. Its human
notes remain the design input for tuning mutation timing and eligibility. The
maintainer has explicitly authorized continuing M11 work while those notes are
pending; no gameplay balance is treated as final by this plan.
## Segments
| Segment | Affected modules | Acceptance evidence |
|---|---|---|
| 11.4a: funded transition proposal | Biology mutation/development public API and implementation; mutation tests; ADR-0118 | Deterministic selection revalidation; exact per-channel body/reserve closure; construction energy charge; insufficient-channel refusal with no partial result; `NDEBUG` tests |
| 11.4b: earned eligibility and offer identity | Cellular life state, tick intake accounting, offer context, profile-4 v2 codec/schema | One offer per 60 seconds of retained fed energy (trial), requesting up to three unranked candidates; exact retry returns the same offer; mismatched offer identity or changed genome/context refuses stale selection; ordinary ticks do not expire an offer; no free rerolls; restore preserves eligibility and offer identity |
| 11.4c: durable mutation publication | Cellular host/session, SQL migration/action parser, replay, crash tests | One action atomically publishes debit, genome successor, organism revision, archive and result; duplicate retry is exact; uncertain commit and process restart have one outcome |
| 11.4d: player choice and review | Engineering client trial UI, replication, playtest notes | Owner sees unranked candidates and actual tradeoffs; choice/refusal/recovery is readable; playtest verifies the choice follows useful feeding rather than appearing at spawn |
## Required checks
- All current M3 mutation and archive tests remain unchanged and pass.
- Test equal inputs and retry after process restore, wrong/stale offers,
unaffordable candidates in each individual channel, overflow, and exact body +
reserve conservation.
- Exercise two candidates that trade construction, maintenance, movement,
ingestion and membrane defense without rendering a ranked score.
- Profile-4 PostgreSQL publication, crash/restart and Linux CI evidence are
required before claiming a live mutation path.
- Record the exploratory 11.3 probe feedback and revisit tuning before widening
candidate options or setting an event cadence.
## Progress
- 11.4a implementation is complete: `fund_mutation` returns a detached,
channel-conserving transition under ADR-0118. CI run 275 passed all 10 jobs
on the current branch, including the configured checks and PostgreSQL jobs.
- The ADR-0108 profile-version conflict is resolved by
[ADR-0119](../adr/0119-cellular-profile-version-migration.md): an explicit,
leased, no-tick v1-to-v2 representation migration initializes mutation state
empty and preserves the complete existing region closure. [ADR-0120](../adr/0120-cellular-mutation-eligibility-trial.md)
defines the first versioned eligibility/offer trial. Their owner and persistence
implementation is the current 11.4b work after the 11.4a CI gate.
- 11.4b implementation now includes version-2 owner snapshots, fed-energy
eligibility, stable offers, manifest/schema admission, the no-tick migration
publisher, immutable migration record, and migration-aware recovery/replay.
Runs 274 and 275 later passed all 10 jobs on the current branch, superseding
the unavailable result from run 261 and validating these changes in CI.
- [ADR-0122](../adr/0122-append-only-cellular-genome-revisions.md) resolves the
archive/current-genome conflict with an append-only revision chain, preserving
birth-genome history, and a cellular-v3 no-tick migration. [ADR-0121](../adr/0121-durable-cellular-mutation-selection.md)
then defines selection and atomic publication. Affected modules are biology
archive API/codec, cellular life owner/snapshot, checkpoint version
bundle/migration, replay trace, SQL action publication, host/session and
crash/retry tests. The archive API/codec, owner v3 snapshot and explicit
no-tick v2-to-v3 manifest/SQL migration are implemented. The current 11.4c
slice adds schema v29's fenced, idempotent mutation reservation and
lease-fenced pending-action recovery API. Selection is still not admitted by
the region host: exact offers, replayed action records, atomic
biology/archive publication and crash recovery remain. No 11.4c or live
mutation path is claimed complete until those pieces pass CI (see
[validation log](VALIDATION.md)).